Anticorps Recombinant de lapin anti-Phospho-INSR (Tyr1146)/IGF1R (Tyr1131)

Phospho-INSR (Tyr1146)/IGF1R (Tyr1131) Recombinant Antibody for WB, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

243066C4

N° de cat : 82830-15-PBS

Synonymes

P IGF1R (Tyr1131), P INSR (Tyr1146), Phos-IGF1R (Tyr1131), Phospho-IGF1R (Tyr1131), Phospho-INSR (Tyr1146)

---

Galerie de données de validation

• 

  WB analysis of HEK-293 using 82830-15-RR (same clone as 82830-15-PBS)

  Non-treated and IGF-1 treated HEK-293 cells were subjected to SDS PAGE followed by western blot with 82830-15-RR (Phospho-INSR (Tyr1146)/IGF1R (Tyr1131) antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with Alpha Tubulin (66031-1-Ig) antibody as loading control. This data was developed using the same antibody clone with 82830-15-PBS in a different storage buffer formulation.

• 

  WB analysis of NIH/3T3 using 82830-15-RR (same clone as 82830-15-PBS)

  IGF-1 treated NIH/3T3 cells were subjected to SDS PAGE followed by western blot with 82830-15-RR (Phospho-INSR (Tyr1146)/IGF1R (Tyr1131) antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with Alpha Tubulin (66031-1-Ig) antibody as loading control. This data was developed using the same antibody clone with 82830-15-PBS in a different storage buffer formulation.

• 

  WB analysis of C6 using 82830-15-RR (same clone as 82830-15-PBS)

  IGF-1 treated C6 cells were subjected to SDS PAGE followed by western blot with 82830-15-RR (Phospho-INSR (Tyr1146)/IGF1R (Tyr1131) antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with Alpha Tubulin (66031-1-Ig) antibody as loading control. This data was developed using the same antibody clone with 82830-15-PBS in a different storage buffer formulation.

---

Informations sur le produit

82830-15-PBS cible Phospho-INSR (Tyr1146)/IGF1R (Tyr1131) dans les applications de WB, Indirect ELISA et montre une réactivité avec des échantillons Humain, rat, souris

• Réactivité: Humain, rat, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Recombinant
• Type: Anticorps
• Immunogène: Peptide
• Nom complet: INSR
• Poids moléculaire observé: 95 kDa
• Numéro d’acquisition GenBank: BC117172
• Symbole du gène: INSR
• Identification du gène (NCBI): 3643
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par protéine A
• Tampon de stockage: PBS only
• Conditions de stockage: Store at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

Insulin binding to the insulin receptor (INSR) triggers sequential conformational changes and autophosphorylation of the receptor, followed by activation of a kinase signaling cascade that plays essential roles in a wide variety of biological processes. INSR belongs to a class of receptor tyrosine kinases (RTKs) that comprises 58 receptors in humans. The INSR shares a high structural homology with the IGF1R (84% similarity in the tyrosine kinase domain, 45-65% in the ligand-binding domain, and more than 50% in the overall amino acid sequence). In addition, ligand-dependent activation of the INSR and IGF1R activates almost identical downstream signaling cascades. Insulin binds to INSR in peripheral tissues, initiating receptor activation followed by intracellular signaling cascades. The first step in INSR activation is the autophosphorylation of intracellular tyrosine residues in the JM domain, kinase activation loop, and CT domain. Phosphorylation of three tyrosine residues (Tyr1146, Tyr1150, and Tyr1151, based on INSR isoform A numbering) located in the kinase activation loop plays a crucial role in kinase activity regulation. Insulin binding also induces INSR kinase-mediated phosphorylation of four tyrosine residues located in the JM (Tyr953 and Tyr960) and CT domain (Tyr1316 and Tyr1322). (PMID: 37779149,PMID:24434591)

{{ptg:RelatedPrimaryAntibodies}}